Welcome to our dedicated page for TECOGEN SEC filings (Ticker: TGEN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on TECOGEN's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into TECOGEN's regulatory disclosures and financial reporting.
Tecogen Inc. reported weaker results for the quarter and six months ended June 30, 2026. For the first half of 2026, total revenues were $12.1 million, down from $14.6 million a year earlier, as Products revenue declined sharply while Services and Energy Production grew modestly. Net loss attributable to Tecogen widened to $4.27 million from $2.12 million, driven by lower gross profit and higher general and administrative and R&D expenses.
Cash and cash equivalents fell to $6.78 million from $12.43 million at December 31, 2025, reflecting $5.46 million of cash used in operating activities in the first half. Total assets were $31.6 million and total liabilities $14.1 million, leaving stockholders’ equity of $17.6 million. The Services segment, supported by acquired Aegis maintenance contracts, remains the largest revenue contributor.
Tecogen Inc. reported weaker results for the quarter and six months ended June 30, 2026. Quarterly revenues were $5.75 million, down 21.2% from 2025, driven by a 64.0% drop in Products revenue to $1.13 million, partly offset by Services growth of 10.3% to $4.38 million and Energy Production growth of 35.4% to $0.24 million. Gross profit was $2.17 million, with gross margin improving to 37.8% from 33.8% on higher Products segment margin.
Loss from operations widened to $2.15 million from $1.41 million, and net loss attributable to Tecogen increased to $2.15 million (loss of $0.07 per share) from $1.46 million (loss of $0.06). Adjusted EBITDA for the quarter was negative $1.68 million, compared with negative $1.16 million a year earlier.
For the first half of 2026, revenues were $12.08 million, down 17.1%, with Products revenue down 59.4% and Services up 9.8%. Net loss for the six months was $4.27 million (loss of $0.14 per share) versus $2.12 million in 2025. Cash and cash equivalents were $6.78 million at June 30, 2026, compared with $12.43 million at year-end. Management highlighted a non–data center backlog of approximately $8 million, expected additional orders of $2 million or more, and recent product demonstrations with large data centers representing more than 8 gigawatts of existing capacity.
Tecogen Inc. approved new equity awards and salary increases for its chief executive and other named executive officers. On June 26, 2026, the Board granted restricted stock and incentive stock options under the 2022 Stock Incentive Plan, including to CEO Abinand Rangesh, who received 174,081 shares of restricted stock and options on 26,041 shares. The awards vest in four equal annual installments and the options are exercisable at $5.17 per share. The Board also raised Mr. Rangesh’s annual base salary by 5% to $220,500, and increased base salaries for the other named officers by 3%, with new annual salaries ranging from $152,260 to $206,000.
Whiting John Kimball IV reported acquisition or exercise transactions in this Form 4 filing.
TECOGEN INC. reported that its General Counsel & Secretary, John Kimball Whiting IV, received a grant of 19,342 shares of Common Stock as a restricted stock award under the 2022 Stock Incentive Plan. The award vests in four equal installments of 25% per year. Following this grant, he directly holds 19,342 shares.
Lafaille Stephen reported acquisition or exercise transactions in this Form 4 filing.
TECOGEN INC. reported that VP of Business Development Stephen Lafaille received a grant of 29,013 shares of common stock as a compensation award. The shares were granted at no cash cost to him and are structured as a Restricted Stock Award under the company’s 2022 Stock Incentive Plan.
The award vests in stages, with 25% of the shares vesting each year, which is designed to encourage long-term alignment with the company’s performance and retention over several years. Following this grant, Lafaille holds 29,013 common shares directly, with no derivative securities reported in this filing.
TECOGEN INC. Chief Accounting Officer Roger P. Deschenes reported an acquisition of 29,013 shares of common stock through a restricted stock award. The award was granted at no cash cost per share and represents his entire directly held position after the transaction. The grant vests in equal 25% installments each year under the company’s 2022 Stock Incentive Plan, meaning the shares become fully owned over four years as service conditions are met.
Tecogen Inc. reported that COO and President Robert Panora received new equity awards. He acquired 9,671 shares of Common Stock as a restricted stock award under the 2022 Stock Incentive Plan, with the grant made at no cash cost to him.
Panora was also granted stock options covering 26,041 shares of Common Stock at an exercise price of $5.17 per share. The options are incentive stock options under the 2022 Stock Incentive Plan, vesting 25% per year and expiring on June 26, 2036. After these grants, his reported direct holdings from this award are 9,671 shares and 26,041 options.
Tecogen Inc. director and CEO Rangesh Abinand received new equity awards in the form of common stock and stock options. He was granted 174,081 shares of common stock as a restricted stock award at no cash cost, vesting 25% per year under the 2022 Stock Incentive Plan. He also received an incentive stock option covering 26,041 shares of common stock at an exercise price of $5.17 per share, which also vests 25% per year and is exercisable until June 26, 2036. Following these grants, his reported direct holdings are 174,081 common shares and options on 26,041 shares.
TECOGEN INC. director Susan B. Hirsch received a compensation-related stock option grant covering 25,000 shares of common stock. The option has an exercise price of $5.17 per share and vests in equal 25% installments per year, providing potential future ownership if exercised. Following this award, Hirsch holds stock options for 25,000 shares directly.
Tecogen Inc. director John M. Albertine received a grant of stock options covering 25,000 shares of common stock. The options have an exercise price of $5.17 per share, vest 25% per year, and are scheduled to expire on June 26, 2036. Following this grant, he holds 25,000 derivative securities directly.